Bios Partners — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)inDavid Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in
BoardAaron Fletcher(Director)in
Co-investorsExSight VenturesInvest MichiganNovartis Venture FundVisionary VenturesInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.